You are here:

rilpivirine/emtricitabine/tenofovir alafenamide (Odefsey)

Advice

following an abbreviated submission:

rilpivirine/emtricitabine/tenofovir alafenamide (Odefsey®) is accepted for use within NHS Scotland.

Indication under review: treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.

For adult patients in whom emtricitabine/rilpivirine/tenofovir is an appropriate combination, Odefsey® (emtricitabine/rilpivirine/tenofovir alafenamide) offers an alternative to Eviplera® (emtricitabine/rilpivirine/tenofovir disoproxil) at no additional cost. Odefsey may also be used in patients from the age of 12 years.

Drug Details

Drug Name: rilpivirine/emtricitabine/tenofovir alafenamide (Odefsey)
SMC Drug ID: 1189/16
Manufacturer: Gilead Sciences Ltd
Indication: treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 10 October 2016

Back